Findings

What do systematic reviews say?

9 questions · 9 findings · 2 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 55.6%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 22.2%Moderate 1 · 11.1%High 1 · 11.1%

Brachytherapy vs brachytherapy plus radiotherapy

Adverse effects · patients with dysphagia in oesophageal cancer

Brachytherapy showed no clear difference in adverse effects compared with brachytherapy plus radiotherapy (moderate certainty).

1 finding from 1 review

Interventions for dysphagia in oesophageal cancer 2014 · Cochrane Headline outcomes only
OR 1.17 [0.44, 3.15]
2 studies · 554 participants
Moderate

Brachytherapy vs brachytherapy plus radiotherapy

Adverse effects ‐ stricture · patients with dysphagia in oesophageal cancer

Brachytherapy showed no clear difference in adverse effects ‐ stricture compared with brachytherapy plus radiotherapy (high certainty).

1 finding from 1 review

Interventions for dysphagia in oesophageal cancer 2014 · Cochrane Headline outcomes only
OR 1.43 [0.16, 12.85]
2 studies · 277 participants
High

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Overall survival · women with recurrent or FIGO stage IVB cervical cancer

Apatinib plus chemotherapy or chemotherapy/brachytherapy showed no clear difference in overall survival compared with chemotherapy or chemotherapy/brachytherapy (low certainty).

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
HR 0.9 [0.51, 1.6]
1 study · 52 participants
Low

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Specific adverse events: gastrointestinal perforations or fistulae ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer

The review found no eligible studies for this question.

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Specific adverse events: haemorrhage · women with recurrent or FIGO stage IVB cervical cancer

The review found no eligible studies for this question.

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Specific adverse events: thromboembolic events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer

The review found no eligible studies for this question.

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Adverse events: hypertension · women with recurrent or FIGO stage IVB cervical cancer

Apatinib plus chemotherapy or chemotherapy/brachytherapy may leads to higher specific adverse events: hypertension compared with chemotherapy or chemotherapy/brachytherapy (low certainty).

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
RR 5.14 [1.28, 20.73]
1 study · 52 participants
Low

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Serious adverse events ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer

The review found no eligible studies for this question.

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Economic evaluation ‐ not measured · women with recurrent or FIGO stage IVB cervical cancer

The review found no eligible studies for this question.

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found